Cyprotex are delighted to announce being awarded Company of the Year at the 14th Bionow Annual Awards on the 26th November 2015. The prestigious ceremony showcases the very best businesses, products, technologies and individuals from the life science industry in the North of the UK. This is the second time Cyprotex have been presented with an award at the event – in 2013 the Company was awarded Service Company of the Year.
The 2015 Company of the Year award, which was sponsored by AstraZeneca, was in recognition of Cyprotex’s achievements in the past year, and was based on the Company’s global expansion, its return to profitability and its success in developing novel technologies for the benefit of the scientific community.
Dr Anthony Baxter, CEO of Cyprotex, commented, ‘We are honoured to win the Bionow Company of the Year award. This is testament to the efforts of all our staff. Their commitment, drive and expertise have been instrumental in the growth and success of the Company.’
For Further Information
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel
Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1300 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe® PK, chemPK™ and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com.